Webcast on Evotec-Sernova partnership


Hamburg, Germany, and London, ON, Canada, 17 May 2022:

Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2. Sernova and Evotec held a joint conference call on the transaction in English.